SEC Tracker
Get the app

Athira Pharma LONA

Athira Pharma FY 2020: net loss $20.0M

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Athira Pharma reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$20.0MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Cash and cash equivalents$60.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  3. Cash from operations−$24.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Athira Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. BioCardia BCDA public float $10M, Jun 30, 2025
  2. Brainstorm Cell Therapeutics BCLI public float $10M, Jun 30, 2025
  3. Abpro Holdings ABP public float $9M, Jun 30, 2025
  4. Adaptin Bio APTN public float $9M, Jun 30, 2025
  5. MiNK Therapeutics INKT public float $11M, Jun 30, 2025